Context: How B3 (Brasil, Bolsa, Balcao) works, and what it makes issuers disclose · Brazil on the LatAm Power Map
Brazil’s largest medical diagnostics network has spent six decades stitching together hospitals, labs, and cancer clinics from São Paulo to Buenos Aires — yet the bill for all that stitching is still coming due, and the company has not turned a net profit in years.
| Full name | Diagnósticos da América S.A. (Dasa) |
| Ticker / exchange | DASA3 — B3 (São Paulo) |
| Headquarters | Barueri, Greater São Paulo, Brazil |
| Sector | Healthcare — Diagnostics & Research |
| Employees | 26,255 |
| Market value (market cap) | R$3.14bn (US$610 mn) (~$609m) |
| Yearly sales (revenue, FY2024) | R$15.32bn (US$3.0 bn) (~$2.97bn) |
| Net profit (FY2024) | –R$1.20bn (US$233 mn) (–$233m loss) |
| Net margin (TTM) | –10.9% (our calculation) |
| Return on equity | –13.8% (EODHD) |
| Price-to-earnings | n/a (loss-making) |
| Dividend yield | None |
| Website | www.dasa3.com.br |
What it is
Diagnósticos da América — known commercially as Dasa — provides diagnostic and hospital services in Brazil and Argentina, operating through three divisions: Hospitals & Oncology; Diagnostics (domestic); and Diagnostics (international).
Founded in 1961, the company is headquartered in Barueri, Greater São Paulo, and is described as the largest medical diagnostics company in Latin America. Its brands run from walk-in pathology labs to full oncology centres, serving patients across dozens of cities under names including Delboni, Lavoisier, and Lâmina.
Who owns it
The holding company Cromossomo II, together with its indirect controlling shareholders Edson de Godoy Bueno and Dulce Pugliese de Godoy, is Dasa’s majority shareholder, holding 71.94% of the company’s capital stock. The Bueno family is the effective controlling power behind the business.
BTG Pactual Asset Management holds approximately 20% of shares outstanding, while Dulce de Godoy Bueno, who also serves as Co-Chairman of the Board, holds roughly 4.8%. Institutional investors, including asset managers, collectively hold the bulk of the remaining float.
Who runs it
The company’s governance page confirms that Rafael Lucchesi is Chief Executive Officer and Rafael Bossolani is Chief Financial and Investor Relations Officer. André Covre holds the role of Corporate Strategy Officer.
Before joining Dasa, CFO Bossolani spent 15 years at the Ultra Group as CFO and CEO of Extrafarma, and also worked at Unisys Corporation in the US and ABN AMRO Capital in Europe; he holds an MBA from INSEAD.
The money, in plain words
Dasa generates serious revenue — R$15.32bn (US$3.0 bn) (~$2.97bn) in FY2024, up 7.5% from 2023 (our calculation) — but the interest bill on its heavy debt pile swallows the operating gains whole. The net loss in FY2024 was R$1.20bn (US$233 mn) (~$233m), a net margin of –7.8% (our calculation); the company has lost money at the bottom line in each of the past three reported years.
The balance sheet tells the story clearly: total debt stands at R$8.84bn (US$1.7 bn) (~$1.72bn) against cash of R$2.67bn (US$518 mn) (~$518m), leaving net debt of R$6.18bn (US$1.2 bn) (~$1.20bn) (our calculation). Every real of operating profit earned — R$1.01bn (US$196 mn) in FY2024 — is more than consumed by financing costs before shareholders see a cent.
Owners’ equity is positive at R$6.87bn (US$1.3 bn) (~$1.33bn), but with losses compounding, return on equity sits at –13.8%. No price-to-earnings ratio is calculable, and no dividend has been paid.
What it is doing now
The most structurally significant recent move was a 2024 agreement with Amil to combine their hospital operations in a 50/50 joint venture spanning 25 hospitals and several oncology clinics. This deal reshapes Dasa from a debt-laden solo operator into a shared-risk partner with one of Brazil’s largest health insurers.
In the most recently reported quarter (Q2 2025), revenue came in at R$2.47bn (US$480 mn), down 38% year-on-year from the same period in 2024, with a net loss of R$176m (US$34 mn). The sharp revenue fall reflects the transfer of hospital assets into the Amil joint venture, which removes those revenues from Dasa’s consolidated accounts.
What to watch
- Joint-venture integration: whether the Amil hospital partnership cuts net debt meaningfully — or simply shifts complexity — is the single most important question for creditors and equity holders alike.
- Debt refinancing: with R$8.84bn (US$1.7 bn) in gross debt and an operating profit of roughly R$1bn (US$194 mn), the cost of rolling or refinancing that debt in Brazil’s still-elevated interest-rate environment will determine whether the company can ever reach the net-profit line.
- Revenue baseline reset: the steep Q2 2025 revenue drop is largely structural (assets out, JV in); watch whether the diagnostic-lab division can grow fast enough to compensate.
- Controlling-family strategy: the Bueno family holds a commanding 71.94% of capital; any decision to sell, recapitalise, or take the company private would move the share price sharply.
Sources
- Dasa Investor Relations — Management, Board and Committees (primary governance page, read directly): https://www.dasa3.com.br/en/governanca-corporativa/board-councils-and-committees/
- Dasa Investor Relations — Corporate History (primary company page, read directly): https://www.dasa3.com.br/en/the-dasa/historic/
- Wikipedia — Diagnosticos da America (cross-reference for JV and founding facts): https://en.wikipedia.org/wiki/Diagnosticos_da_America
- Market data: EODHD.
This is news, not investment advice.
Read More from The Rio Times